Reversing anticoagulant therapy

Area of Science:

• Pharmacology
• Hematology
• Critical Care Medicine

Background:

• Heparin and warfarin have been mainstays for over 50 years, with established antidotes.
• Novel anticoagulants offer potential advantages but lack specific reversal agents.
• Managing bleeding with novel anticoagulants requires understanding nonspecific procoagulant strategies.

Purpose of the Study:

• To review novel anticoagulants and the evidence for their reversal.
• To provide recommendations for managing major bleeding associated with novel anticoagulants.
• To highlight the need for physician understanding of reversal strategies in the absence of specific antidotes.

Main Methods:

• Review of existing literature on novel anticoagulants and their reversal.
• Extrapolation from animal models and clinical data.
• Analysis of procoagulant agents like PCCs and rFVIIa for reversal efficacy.

Main Results:

• Activated PCCs are recommended first for direct thrombin inhibitor (DTI) bleeding, followed by rFVIIa and non-activated PCCs.
• Recombinant factor VIIa shows rationale for managing fondaparinux-associated bleeding.
• Evidence for reversal is based on extrapolation, anecdote, and mechanism of action.

Conclusions:

• Nonspecific procoagulants are crucial for managing bleeding with novel anticoagulants.
• Physicians need to understand rational approaches to reverse novel anticoagulant effects.
• The increasing use of novel anticoagulants necessitates preparedness for managing bleeding complications.